

DIPARTIMENTO

SCIENZE MEDICHE E CHIRURGICHE – DIMEC



Centro unificato di  
Ricerca Biomedica applicata

# *La steroidologia nell'epoca della cromatografia liquida abbinata alla spettrometria di massa: successi, limiti e nuovi orizzonti*

**Flaminia Fanelli**

Medical Biotechnologist, PhD


Unit of Endocrinology and Prevention and Care of Diabetes

Center for Applied Biomedical Research

Department of Medical and Surgical Sciences

Alma Mater Studiorum University of Bologna


Bologna, Italy





***Adrenal tumors***



***Hypogonadism  
Osteoporosis***



***Hypertension  
Cardiovascular risk  
Obesity  
Diabetes***



A

B

C

D

# STEROID HORMONES



***Reproduction***

***Hyperandrogenism***





***Genetic deficit  
steroidogenesis  
Disorder of Sex  
Development***




# STEROID STRUCTURE and CLASSIFICATION


cyclopentane perhydrophenanthrene




PROGESTOGENS




GLUCOCORTICOIDS




MINERALOCORTICOIDS



ESTROGENS



ANDROGENS




C21

C18

C19

# PERFORMANCE REQUIREMENTS for STEROID HORMONE MEASUREMENT



**SPECIFICITY** vs hundreds of endogenous and exogenous steroids

- Structural related or unrelated isobars, isomers, epimers, conjugated metabolites
- Drugs

**SENSITIVITY** and **WIDE DYNAMIC RANGE**

- Gender: in females and in males
- Fertility status: Menstrual phase / Pregnancy / Menopause
- Functional tests: adrenal stimulation and suppression


**ACCURACY** and **PRECISION** small but clinically relevant intra- and inter-individual variations

- Differential diagnosis,
- Monitoring therapy / hormone replacement


Requests by clinicians include **PANEL** rather than single steroids

Ideally **NO INFLUENCE** from different MATRIX

# QUANTITATIVE ANALYTICAL TECHNIQUES FOR STEROID MEASUREMENT




# PITFALLS in DIRECT IMMUNOASSAYS





- **Cross reactivity**
- release from **binding protein**
- **matrix interference**
- **Anti-reagent Ab** (heterophilic Ab)
- **Biotine** supplementation
- **Narrow dynamic range**

TESTOSTERONE:  
pg/ml – ng/ml



DHEA-S:  
μg/ml





Specific Interaction




Cross-reactivity



Interference



# TESTOSTERONE IN THE IMMUNOASSAY AGE



**Immunoassays  
VS  
GC-MS reference method**

# **DIRECT IMMUNOASSAY in the ROUTINE LAB**

**HIGH COSTS**




**SERIOUS  
UNCERTAINTIES**

**Diagnosis  
Therapy**



# COLUMN CHROMATOGRAPHY – MASS SPECTROMETRY

## GAS (GC)




HIGH SEPARATION  
HIGH SPECIFICITY

*but*

**POOR VERSATILITY**

## LIQUID (LC)




GOOD SEPARATION  
GOOD SPECIFICITY

*and*

**HIGH VERSATILITY**


# GAS CHROMATOGRAPHY



GAS phase      High temperature



Analytes need to be volatile and thermostable





COMPROMISE:  
DERIVATIZATION



Long reaction time.  
Extensive sample purification.

# THE POWER OF LC-MS/MS


## ISOTOPIC DILUTION



## 3 SPECIFICITY STEPS



## MULTIANALYTE DETECTION




1. HPLC  
RETENTION  
TIME

2. MS1  
MOLECULAR  
WEIGHT

3. MS2  
STRUCTURE

## LARGE DYNAMIC RANGE

5 orders of magnitude



## SENSITIVITY



## SPECIFICITY




# UNIBO/CRBA IN HOUSE METHODS FOR STEROID PROFILING

API 4000 QTrap




Panel 1: 11 steroids in serum





Fanelli et al.,  
Steroids 2011

Panel 2: 4 steroids in serum




Mezzullo et al.,  
SBMB 2020

Panel 3: Salivary glucocorticoids



Mezzullo et al.,  
SBMB 2016


Panel 4: Salivary androgens



Mezzullo et al.,  
CCLM 2017

Panel 5: 21 steroids from Leydig cells  
(Canonical and backdoor androgen pathways)

Fanelli et al., SBMB 2023







# **THE SUCCESS of LC-MS/MS in the last 20y**

- **Improving the measurement of traditional diagnostic steroids**
- Allowing the measurement of steroid panels
- Easing the path toward harmonization of measurements


## State-of-the-Art of Serum Testosterone Measurement by Isotope Dilution– Liquid Chromatography– Tandem Mass Spectrometry

Linda M. Thienpont,<sup>1\*</sup> Katleen Van Uytvanghe,<sup>1</sup> Stuart Blincko,<sup>2</sup> Carol S. Ramsay,<sup>3</sup> Hui Xie,<sup>3</sup>  
Robert C. Doss,<sup>3</sup> Brian G. Keevil,<sup>4</sup> Laura J. Owen,<sup>4</sup> Alan L. Rockwood,<sup>5,6</sup> Mark M. Kushnir,<sup>5</sup> Kelly Y. Chun,<sup>7</sup>  
Donald W. Chandler,<sup>7</sup> Helen P. Field,<sup>8</sup> and Patrick M. Sluss<sup>9</sup>




# FEMALE HYPERANDROGENISM

## 5-10% of women in reproductive age





### Serum TESTOSTERONE



- Routine lab - IA cut-off: 0.70 ng/mL
- LC-MS/MS cut-off: 0.45 and 0.50 ng/mL

N=295 patients (18 – 54y) referring for:  
Hirsutism, Menstrual irregularities,  
Infertility or Obesity



*Fanelli et al., unpublished data*

# ADRENAL INCIDENTALOMA


4-10% of the population

DEXAMETHASONE SUPPRESSION TEST FOR THE  
DIAGNOSIS OF MILD AUTONOMOUS CORTISOL SECRETION




## ELECSYS E170

5% possible false positives.  
6.5% possible false negatives.



## DXI 800

0.9% possible false positives.  
4.6% possible false negatives.




N° of DST at our Unit in Bologna: 40 per month.

2 patients per month potentially wrongly discharged....

# THE SUCCESS of LC-MS/MS in the last 20y

- Improving the measurement of traditional diagnostic steroids
- **Allowing the measurement of steroid panels**
- Easing the path toward harmonization of measurements

# CONGENITAL ADRENAL HYPERPLASIA





Hormones measured in the routine lab


Hormones NOT measured in the routine lab

# CONGENITAL ADRENAL HYPERPLASIA

## DIFFERENTIATION NON CLASSIC CAH FORM PCOS IN ADOLESCENT AND ADULT WOMEN



### 17OH-PROGESTERONE RIA vs LCMSMS




Fanelli et al., Steroids 2011

Hormones measured in the routine lab

Hormones NOT measured in the routine lab

# CONGENITAL ADRENAL HYPERPLASIA

## DIFFERENTIATION NON CLASSIC CAH FORM PCOS IN ADOLESCENT AND ADULT WOMEN



Hormones measured in the routine lab  
Hormones NOT measured in the routine lab

Unconventional RE-DISCOVERED steroids

# DIAGNOSING 21-NCAH by LC-MS/MS STEROID PROFILING

**Table 2** Comparison of steroid concentrations between patients with nonclassic 21-hydroxylase deficiency (N21OHD) and controls. Data are expressed as median (interquartile range).

| Steroid (nmol/L)  | N21OHD (n = 32)     | Controls (n = 54)   | Ratio of medians N21OHD/controls | P       |
|-------------------|---------------------|---------------------|----------------------------------|---------|
| 17OHP4            | 18.1 (8.7–33.0)     | 2.8 (0.9–4.3)       | 6.5                              | <0.0001 |
| 16OHP4            | 2.4 (1.4–4.9)       | 0.6 (0.4–0.9)       | 4.1                              | <0.0001 |
| 21dF              | 1.8 (1.3–5.3)       | 0.0 (0.0–0.3)       | N/A                              | <0.0001 |
| Progesterone      | 0.8 (0.5–1.4)       | 0.4 (0.3–0.8)       | 1.8                              | 0.0018  |
| Cortisol          | 202.5 (125.9–442.8) | 249.1 (208.9–373.7) | 0.8                              | 0.197   |
| Cortisone         | 53.7 (30.5–72.3)    | 51.5 (40.3–60.8)    | 1.0                              | 0.855   |
| Corticosterone    | 1.6 (0.8–3.5)       | 5.9 (3.5–13.6)      | 0.3                              | <0.0001 |
| 11dF              | 0.8 (0.5–1.4)       | 0.9 (0.4–1.6)       | 0.8                              | 0.626   |
| DOC               | 0.3 (0.3–0.4)       | 0.5 (0.4–0.9)       | 0.6                              | 0.113   |
| A4                | 4.3 (2.0–8.1)       | 3.9 (2.2–8.5)       | 1.1                              | 0.798   |
| Testosterone      | 1.1 (0.5–2.7)       | 1.6 (0.8–4.3)       | 0.7                              | 0.195   |
| 11OHA4            | 9.6 (5.1–25.9)      | 4.5 (2.9–7.1)       | 2.1                              | <0.0001 |
| 11KA4             | 1.1 (0.7–1.7)       | 0.6 (0.4–0.8)       | 1.7                              | 0.0001  |
| 11OHT             | 1.0 (0.3–1.7)       | 0.4 (0.3–0.6)       | 2.2                              | 0.0019  |
| 11KT              | 1.8 (1.2–3.3)       | 0.9 (0.6–1.3)       | 2.0                              | <0.0001 |
| 11KT/Testosterone | 1.8 (1.2–3.0)       | 0.6 (0.2–0.9)       | 3.3                              | <0.0001 |
| 11OHA4/A4         | 2.6 (2.1–4.6)       | 1.2 (0.7–2.1)       | 2.0                              | <0.0001 |
| A4/testosterone   | 3.8 (2.8–4.5)       | 3.5 (2.4–4.2)       | 1.3                              | 0.274   |

A4, androstenedione; DOC, 11-deoxycorticosterone; 17OHP4, 17 $\alpha$ -hydroxyprogesterone; 16OHP4, 16 $\alpha$ -hydroxyprogesterone; 21dF, 21-deoxycortisol; 11dF, 11-deoxycortisol; 11OHA4, 11 $\beta$ -hydroxyandrostenedione; 11KA4, 11-ketoandrostenedione; 11OHT 11 $\beta$ -hydroxytestosterone; 11KT, 11-ketotestosterone.

*Turcu et al., EJE 2020*

## 21-NCAH vs PCOS

**High 21-deoxycortisol**

$\geq 0.087$  ng/mL

100% sensitivity

76.9% specificity

**High 17OHP4**  $\geq 1.79$  ng/mL  
**plus**

**Low Corticosterone**  $\leq 8.76$  ng/mL

72.7% sensitivity  
100% specificity

41.9%

true negative

PCOS women not needing  
further genetic analysis or ACTH  
testing

*Oriolo et al., JEI 2020*


# THE SUCCESS of LC-MS/MS in the last 20y

- Improving the measurement of traditional diagnostic steroids
- Allowing the measurement of steroid panels
- **Easing the path toward harmonization of measurements**

# REPRODUCIBILITY OF STEROID MEASUREMENTS


## TESTOSTERONE

7 labs using IAs




*Groenestegte et al., Clin Chem 2012*

9 LC-MS/MS assays



*Vesper et al., Steroids 2009*

# LC-MS/MS is a COMPLEX MULTISTEP PROCEDURE



Blood  
collection

Sample  
prep

Isotopic  
Internal  
Standard

LC  
Separa  
tion

Ioniza  
tion

Parent  
Ion filter

Analyte  
fragmen  
tation

Daughter  
Ion filter

Quanti  
tation


*Multiple options available for each step.*

*Several technical differences among LC-MS/MS assays.*

➤ What is the Impact on the final result?

# HarmoSter CONSORTIUM

*9 Measuring Centers all over Europe*  
*9 different LC-MS/MS assays*



**University of Bologna, IT**



**Manchester NHS Foundation Trust, UK**



**Amsterdam University Medical Center, NL**



**Canisius-Wilhelmina Hospital, Nijmegen, NL**



**Technische Universität Dresden, DE**



**University Hospital, Erlangen, DE**



**Hospital of the University of Munich, DE**




**University Hospital of Lausanne, CH**



**Ente Ospedaliero Cantonale, Bellinzona, CH**

# INTER-LABORATORY VARIABILITY


----- *Maximum allowable imprecision*



# THE LIMITS


## SOURCES OF VARIABILITY IN RESULTS BY DIFFERENT LC-MS/MS METHODS

Interaction among analytical factors and individual patient sample within each methods.






# THE LIMITS

## STEROID CROSS-DETECTION in LC-MS/MS





Extended run-times to separate steroids with the same molecular weight and similar MS/MS spectrum



# EXPLORING THE STEROIDOME


## THE BACKDOOR PATHWAY FOR ANDROGEN BIOSYNTHESIS



- 16OH-Progesterone (16OH-P4)
- 11-Deoxycortisol (11-S)
- Androstenedione (A4)
- 11-Deoxycorticosterone (11-DOC)
- Testosterone (T)
- Androstenediol (A5)
- 17OH-Progesterone (17OH-P4)
- 17OH-Pregnenolone (17OH-P5)
- Dehydroepiandrosterone (DHEA)
- Androstenedione (5α-dione)
- Epitestosterone (Epi-T)
- Dihydrotestosterone (DHT)
- 17OH-Dihydroprogesterone (17OH-DHP4)
- Progesterone (P4)
- Androstenediol (3α-diol)
- Androsterone (AN)
- Pregnenolone (P5)
- Dihydroprogesterone (5α-DHP4)
- 17OH-Allopregnanolone (17OH-Allo)
- Allopregnanolone (Allo)

# THE LIMITS

## VARIABLE SENSITIVITY FOR DIFFERENT STEROIDS













# **FUTURE PERSPECTIVES** **FOR CLINICAL LABORATORIES**

- Ready to use kits including SPE plates, calibrators, internal standard, reagents, etc...  
CE-IVD
- Fully automated solutions combining  
sample prep + LC-MS/MS

# FUTURE PERSPECTIVES



## «STEREIDOMICS»

### HETEROGENEITY IN STUDY DESIGN AND ANALYTICAL APPROACH




# UNTARGETED WORKFLOW FOR UNTARGETED METABOLOMICS


WORK IN PROGRESS



## Pathways analysis



Vanquish Flex  
Orbitrap Exploris 240



# STEROID ANALYTICALS

## THE ON GOING (R)EVOLUTION

### PAST

Immunoassays



**Single** analyte measurement  
of a few steroids



High Throughput  
Poor specificity



Reference interval  
Decision Limits

### PRESENT

LC-MS/MS



**Targeted** measurement of  
panels of steroids



High Specificity and Sensitivity  
Good Throughput



Combination of multiple RI  
and DL

### FUTURE

LC-High Resolution MS



**Untargeted** analysis of all  
steroids in a certain matrix



Top Specificity  
Good Throughput





Multidimensional Model



## Bologna Team

Division of Endocrinology and Prevention and Care of Diabetes,  
Dept. of Medical and Surgical Sciences, University of Bologna



*Valentina Bissi  
Greta Galante  
Thomas Senard  
Lorenzo Tucci  
Kimberly Coscia  
Laura Rotolo  
Guido Di Dalmazi  
Valentina Vicennati  
Alessandra Gambineri  
Uberto Pagotto*